Patient and public perspectives on cell and gene therapies: a systematic review

Olalekan Lee Aiyegbusi (), Karen Macpherson, Lauren Elston, Susan Myles, Jennifer Washington, Nisha Sungum, Mark Briggs, Philip N. Newsome and Melanie J. Calvert
Additional contact information
Olalekan Lee Aiyegbusi: University of Birmingham
Karen Macpherson: Healthcare Improvement Scotland
Lauren Elston: Health Technology Wales
Susan Myles: Health Technology Wales
Jennifer Washington: Health Technology Wales
Nisha Sungum: Birmingham Health Partners Centre for Regulatory Science and Innovation
Mark Briggs: Velindre University NHS Trust
Philip N. Newsome: University of Birmingham
Melanie J. Calvert: University of Birmingham

Nature Communications, 2020, vol. 11, issue 1, 1-9

Abstract: Abstract Cell and gene therapies offer opportunities for treating disease with potential to restore function, and cure disease. However, they are not without risk and pose complex logistical, economic, ethical and social challenges for health systems. Here we report our systematic review of the current evidence on patient and public knowledge and perspectives of cell and gene therapies, to inform future research, education and awareness raising activities. We screened 10,735 titles and abstracts, and evaluated the full texts of 151 publications. The final selection was 35 publications. Four themes were generated from the narrative synthesis of the study findings namely: (1) Knowledge and understanding of cell and gene therapies, (2) Acceptance of cell and gene therapies (3) Understanding of risk and benefits of therapy, and (4) Information needs and current sources of information. As potential funders or future recipients, it is important that the public and patients are aware of these therapies, understand the issues involved, and can contribute to the debate. This review highlights the need for appropriate patient and public education on the various aspects of cell and gene therapies. High quality studies exploring patient and public opinions and experiences of cell and gene therapy are required. Patient and public perceptions of these therapies, alongside evidence of clinical and cost-effectiveness, will be central to their uptake and use.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-20096-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-20096-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-20096-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().